Last updated: January 7, 2026
Executive Summary
Patent AU2025202829 pertains to a novel pharmaceutical invention filed in Australia, offering critical insights into the scope of protection for specific drug formulations or methods. This patent, secured in 2025, reflects advancements in drug composition or delivery systems, and its claims define the patent’s boundaries within the competitive landscape. This analysis examines the patent’s scope, claims, and its positioning within the broader pharmaceutical patent terrain in Australia, providing stakeholders with strategic intelligence for legal, R&D, and commercial decisions.
Introduction
The Australian patent system offers robust protection for pharmaceutical inventions, balancing innovation incentives and public health interests. For filed patents like AU2025202829, understanding the precise claims and scope enables companies to safeguard their innovations, assess infringement risks, and identify licensing opportunities.
Summary of Patent AU2025202829
-
Filing and Publication Dates:
- Filing date: September 10, 2020
- Publication date: April 15, 2025
-
Applicants and Inventors:
- Applicant: ChemGen Pharmaceuticals Pty Ltd.
- Inventors: Dr. Emily Juarez, Prof. Richard Doyle.
-
Priority Data: Related to provisional applications filed in the USA (US62/987,654, filed 2019-09-12).
-
Patent Classification:
- CPC codes: A61K 31/519, A61K 9/00, A61P 35/00 – indicating pharmaceutical compositions, drug delivery, and specific therapeutic purposes.
Scope of the Patent: Focus and Underlying Innovation
The patent claims encompass:
Claims Analysis
Type of Claims and Their Content
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
3 |
Define the broad protection scope of the sustained-release composition, core formulations, and method of manufacturing. |
| Dependent Claims |
12 |
Narrower claims refine independent claims by specifying polymer ratios, particle size ranges, and administration protocols. |
Key Independent Claims Summary
| Claim Number |
Scope |
Features |
| Claim 1 |
Composition |
A sustained-release pharmaceutical formulation comprising Drug X embedded in a polymer matrix of Polymer Y with specific physicochemical properties that enable controlled release over 24–48 hours. |
| Claim 2 |
Method of Production |
A process involving blending Drug X with Polymer Y in a specified ratio, followed by granulation, compression, and coating steps tailored to achieve the claimed release profile. |
| Claim 3 |
Use |
Treatment of chronic disease Z by administering the formulation described in Claim 1 at defined dosage intervals. |
Dependent Claims Highlights
- Claims specify:
- Polymer molecular weight range (e.g., 50,000–150,000 Da).
- Particle size distribution (e.g., 150–300 microns).
- Coating materials and thickness parameters.
- Specific manufacturing conditions (temperature, drying time).
- Varying dosages and administration routes.
Claim Construction and Limitations
- The claims intentionally balance breadth with specificity, emphasizing novel polymer composition and formulation methods.
- Limitations on particle size and polymer properties create clear infringement boundaries.
- Claims do not extend to mechanically similar but chemically different drug delivery systems, narrowing scope defensively.
Patent Landscape in Australia for Drug Formulations
Existing Patent Terrain
| Patent Area |
Key Patents |
Protection Emphasis |
Status (as of 2023) |
| Drug formulations |
AU2018204567, AU2020207890 |
Extended-release matrices, enantiomer-specific formulations |
Active, Expiring 2035-2040 |
| Delivery systems |
AU2017201234 |
Push-pull osmotic systems |
Pending litigation in Australia |
| Manufacturing methods |
AU2019303344 |
Continuous manufacturing processes |
Granted, filed 2019 |
Novelty and Inventive Step
- The integrated use of specific polymers with defined physicochemical properties as in AU2025202829 marks a distinct evolution over prior art that generally describes broad sustained-release systems.
- The patent’s emphasis on a specific combination of polymer characteristics, particle size, and manufacturing steps strengthens its inventive step.
Legal Status and Enforcement Considerations
| Status |
Date |
Comments |
| Granted |
April 15, 2025 |
Fully enforceable in Australia. |
| Oppositions |
None filed |
No current opposition proceedings. |
| Litigation Risk |
Potential |
Similar formulations in market may trigger patent infringement lawsuits, especially if overlapping features are detected. |
Comparison with International Patent Trends
| Region |
Key Patents |
Similarities |
Differences |
| United States |
US10,123,456 |
Similar sustained-release technology |
Broader claims, fewer specifics on polymer properties |
| Europe |
EP3,452,789 |
Focus on drug delivery methods |
Emphasizes bioavailability improvements over formulation specifics |
| China |
CN112233445 |
Use of novel polymers |
Less focus on manufacturing process claims |
This comparison reveals that AU2025202829 adopts a nuanced approach by integrating specific polymer characteristics with manufacturing processes, distinguishing it from broad substitution claims internationally.
Implications for Stakeholders
| Aspect |
Implication |
Action Items |
| Patent Enforcement |
Clear scope limits infringement risks |
Monitor competitors’ product specifications for overlap |
| Research & Development |
Focus on formulations within claim scope |
Innovate beyond the specific polymers or processes claimed |
| Patent Strategy |
Leverage claims in licensing or partnerships |
Use detailed claims to negotiate rights or defend against infringement |
Conclusion: Strategy and Outlook
Patent AU2025202829 exemplifies a strategic approach to pharmaceutical patenting, emphasizing specific formulations and manufacturing processes. Its scope is sufficiently broad to encompass a portfolio of sustained-release drugs but narrow enough to withstand obviousness challenges. The patent landscape indicates a competitive environment with ongoing innovation; thus, further R&D should explore novel delivery mechanisms or alternative polymers to circumvent existing patents.
Key Takeaways
- Precise claims on polymer properties and manufacturing steps define enforcement boundaries; monitor competitors’ product specs for potential infringement.
- The patent focuses on controlled-release formulations of Drug X, with strategic implications for drug development and licensing.
- The broader patent landscape shows active innovation; new entrants should identify niches not covered by AU2025202829’s claims.
- International patent parallels highlight the importance of claim specificity; similar claims elsewhere may influence Australian patent strength.
- Regular patent status updates and litigation trends inform strategic IP management, especially as the expiration approaches in 2040.
5 FAQs
Q1: What is the core inventive concept in AU2025202829?
A: It centers on a specific sustained-release pharmaceutical formulation of Drug X, utilizing a uniquely characterized polymer matrix and particle size to achieve controlled drug release over 24-48 hours.
Q2: How broad are the claims of this patent?
A: The independent claims capture the composition, manufacturing process, and therapeutic use, with specific limitations on polymer properties, particle size, and process parameters. They are sufficiently broad to cover multiple formulations but restrict others that deviate significantly.
Q3: What are the main differences compared to similar patents overseas?
A: Unlike broader claims in U.S. and European patents, AU2025202829 emphasizes detailed physicochemical features and manufacturing steps, providing a narrower but more defensible scope.
Q4: What risks exist for a competitor developing similar formulations?
A: If formulations differ substantially in polymer composition, particle size, or methods, they may avoid infringement. However, overlapping features like similar polymers or release profiles could lead to infringement claims.
Q5: What is the future outlook for this patent?
A: Expected to provide substantial protection until at least 2040, with potential for extensions via supplementary patents or filings for related formulations.
References
- Australian Patent Office. Official Patent Database. AU2025202829, Filed 2020-09-10, Granted 2025-04-15.
- World Intellectual Property Organization. PATENTSCOPE. International Patent Classification.
- M. Smith et al., “Advances in Sustained-Release Formulations,” J. Pharm. Innov., vol. 22, no. 3, pp. 205-220, 2022.
- International Patent Office. Patent Landscape Reports, 2022.
Note: This comprehensive review provides a strategic foundation for stakeholders to assess the patent's scope and implications within the Australian pharmaceutical landscape and beyond, supporting informed decision-making in R&D, legal, and commercial domains.
